Palifermin reduces diarrhea and increases survival following Irinotecan treatment in tumor-bearing DA rats

International Journal of Cancer

Volumn 116, Issue 3, 2005, Pages 464-470

  Gibson, Rachel J ^a,b   Bowen, Joanne M ^a,b   Keefe, Dorothy M K ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Diarrhea; Irinotecan; Mucositis; Palifermin

Indexed keywords

IRINOTECAN; PALIFERMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; COLON; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG TOLERABILITY; HISTOPATHOLOGY; JEJUNUM; LARGE INTESTINE; MITOSIS; MORPHOMETRICS; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SMALL INTESTINE; SURVIVAL RATE; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DIARRHEA; FEMALE; FIBROBLAST GROWTH FACTOR 7; FIBROBLAST GROWTH FACTORS; KERATINOCYTES; MAMMARY NEOPLASMS, ANIMAL; RATS; SURVIVAL ANALYSIS;

EID: 22244474254     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21082     Document Type: Article

References (34)

1. Keefe DM. Gastrointestinal mucositis: a new biological model. Support Care Cancer 2003;23:6-9.
2. Keefe DM, Brealey J, Goland GJ, Cummins AG. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000;47:632-7.
3. Pico J-L, Avila-Garavito A, Naccache P, Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 1998;3:446-51.
4. Benson AB III, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, Mitchell EP, O'Dorisio TM, Yokes EE, Wadler S, Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22:2918-26.
5. Stern J, Ippoliti C, Management of acute cancer treatment-induced diarrhea. Semin Oncol Nurs 2003;19(4 Suppl 3):11-16.
6. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A, Relationship between development of diarrhea and the concentration of SN-38, and active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 1993;84:697-702.
7. Cao S, Black JD, Troutt AB, Rustum YM. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. Cancer Res 1998;58:3270-4.
8. Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DMK. Irinotecan causes severe small intestinal damage as well as colonic damage in the rat with implanted breast cancer. J Gastroenterol Hepatol 2003;18;1095-100.
9. Ikuno N, Soda H, Watanabe M, Oka M. Irinotecan (CPT-11) and characteristic changes in the mouse ileum and cecum. J Natl Caner Inst 1995;87:1876-83.
10. Farrell CL, Rex KL, Chen JN, Bready JV, DiPalma CR, Kaufman SA, Rattan A, Scully S, Lacey DL. The effects of keratinocyte growth factor in preclinical models of mucositis. Cell Prolif 2002;35:78-85.
11. Farrell CL, Rex KL, Kaufman SA, DiPalma CR, Chen JN, Scully S, Lacey DL. Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int J Rad Biol 1999;75:609-20.
12. Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL, Yin S, Hill DC, Wiemann B, Starnes CO, Havill AM, Lu ZN, et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998;58:933-9.
13. Housley RM, Morris CF, Boyle W, Ring B, Blitz R, Tarpley JE, Aukerman SL, Devine PL, Whitehead RH, Pierce GF. Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J Clin Invest 1994;94:1764-77.
14. Dorr W, Spekl K, Farrell CL. The effect of keratinocyte growth factor on healing of manifest radiation ulcers in mouse tongue epithelium. Cell Prolif 2002;35:86-92.
15. Dorr W, Spekl K, Farrell CL. Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int J Rad Oncol Biol Phys 2002;54:245-51.
16. Clarke SJ, Abdi E, Davis D. Recombinant human keratinocyte growth factor (rHuKGF) prevents chemotherapy-induced mucositis in patients with advanced colorectal cancer: a randomized phase II trial. Proc ASCO 2001;20:383A.
17. Durrant S, Pico J-L, Schultz N. A phase 1 study of recombinant keratinocyte growth factor (rHuKGF) in lymphoma patients receiving high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation. Blood 1999;94(Suppl 1): 708A.
18. Speilberger RT, Stiff P, Emmanoulides C. Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning-results of a phase 2 trial. Proc ASCO 2001;20:7A.
19. Stiff P. Oral mucositis in the cancer treatment setting: prospects for improved management. Miami Beach, FL: MASCCASOO Educational Session, Neutropenia, Anemia and Mucositis: Prospects of Improved Supportive Care, 2004.
20. Dorr W, Noack R, Spekl K, Farrell CL. Amelioration of radiation-induced oral mucositis by keratinocyte growth factor (rhKGF): experimental studies. Int J Rad Oncol Biol Phys 2000;46:729-35.
21. Dorr W, Noack R, Spekl K, Farrell CL. Modification of oral mucositis by keratinocyte growth factor: single radiation exposure. Int J Rad Biol 2001;77:341-6.
22. Dorr W. Modification of acute radio (chemo) therapy effects in squamous epithelia by keratinocyte growth factor. Radiother Oncol 2001;60:S8.
23. Gibson RJ, Keefe DMK, Clarke JM, Regester GO, Thompson FM, Goland GJ, Edwards BE, Cummins AG. The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Can Chem Pharmacol 2002;50:53-8.
24. Gibson RJ, Keefe DMK, Thompson FM, Clarke JM, Goland GJ, Cummins AG. Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 2002;47:2751-7.
25. Cummins AG, LaBrooy JT, Stanley DP, Rowland R, Shearman DJC. A quantitative histological study of enteropathy associated with HIV infection. Gut 1990;31:317-21.
26. Harper JF. Peritz' F test: basic programme of a robust multiple comparison test for statistical analysis of all differences among group means. Comput Biol Med 1994;14:437-45.
27. Abigerges D, Armand JP, Chabot GG, DaCosta L, Fadel E, Cote C, Heraot P, Gandia D. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhoea. J Natl Can Inst 1994;86:446-9.
28. Viele CS. Overview of chemotherapy-induced diarrhea. Semin Oncol Nurs 2003;19(4 Suppl 3):2-5.
29. Playford RJ, Marchbank T, Mandir N, Higham A, Meeran K, Ghatei MA, Bloom SR, Goodlad RA. Effects of keratinocyte growth factor (KGF) on gut growth and repair. J Pathol 1998;184:316-22.
30. Dorr W, Spekl K, Farrell CL. The effect of keratinocyte growth factor on healing of manifest radiation ulcers in mouse tongue epithelium. Cell Prolif 2002;35(Suppl 1):86-92.
31. Pritchard DM, Potten CS, Hickman JA. The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia. Cancer Res 1998;58:5453-65.
32. Ulich TR, Yi ES, Cardiff R, Yin S, Bikhazi N, Blitz R, Morris CF, Pierce GF. Keratinocyte growth factor is a growth factor for mammary epithelium in vivo the mammary epithelium of lactating rats is resistant to the proliferative action of kerationcyte growth factor. Am J Pathol 1994;144:862-8.
33. Rubenstein EB, Peterson DE, Schubert MM, Keefe DM, McGuire DB, Epstein JB, Elting LS, Fox PC, Loprinzi CL, Sonis ST. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004;100;2026-46.
34. Sonis ST, Elting LS, Keefe DM, Peterson DE, Schubert MM, Hauer-Jenson M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004;100:1995-2025.